Summary of outcome data by type of regimen received. For progression to LRI: AR alone versus AR plus immunomodulators or IR or OR with or without immunomodulators. P = .13. AR indicates aerosolized ribavarin; IR, intravenous ribavarin; and OR, oral ribavarin.